Nurix

Roche
Biotech

Roche bets $700M upfront on Nurix’s late-phase BTK degrader

Roche is securing a stake in a BTK degrader that is set to go head-to-head against Eli Lilly’s Jaypirca in a phase 3 blood cancer trial.
Nick Paul Taylor Jun 8, 2026 4:41am
Job cuts employee layoffs firings or downsizing Scissors dividing individuals positioned on colorful blocks

Nurix trims staff as trial for lead BTK degrader kicks off

Nov 21, 2025 5:05am
Photo of apples growing on branches with the sun shining in the background

Sanofi pays $15M for another STAT6 degrader from Nurix collab

Jun 2, 2025 9:50am
Paraglider over a snowy mountain

J&J innovator vaults to Valo—Chutes & Ladders

Apr 11, 2025 8:30am
Graphic of two hands shaking under a red and purple light

Sanofi pays Nurix $15M upfront for autoimmune degrader

Apr 2, 2025 8:10am
photo of a paraglider in the foreground with the alps in the background

Flagship vet plants CEO roots at Pharming—Chutes & Ladders

Jan 24, 2025 8:30am